Litigation Details for Richard v. Shire US, Inc. (D. Mass. 2017)
✉ Email this page to a colleague
Richard v. Shire US, Inc. (D. Mass. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-01-24 |
| Court | District Court, D. Massachusetts | Date Terminated | 2022-01-26 |
| Cause | 28:1332 Diversity-Tort/Non-Motor Vehicle | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,287,599; 6,811,794 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Richard v. Shire US, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Richard v. Shire US, Inc. (D. Mass. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-01-24 | External link to document | |||
| 2017-01-23 | 1 | method-of-use patent, and U.S. Patent Nos. 6,287,599 (‘599 Patent) and 6,811,794 (‘794 Patent), which cover…Shire’s Intuniv patent portfolio consists of U.S. Patent Nos. 5,854,290 (‘290 Patent), which is a now-invalidated…applied a patent procurement strategy known as “evergreening.” “Evergreened” patents are patents not on …method-of-use patent (‘290 Patent) of guanfacine hydrochloride and two extended release formulation patents (‘599…-of-Use Patent 57. Shire asserted all three (3) patents, including the ‘290 Patent, against | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
